|Bid||112.56 x 900|
|Ask||113.55 x 800|
|Day's Range||112.07 - 113.62|
|52 Week Range||81.66 - 114.46|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||32.12|
|Earnings Date||Feb 18, 2020|
|Forward Dividend & Yield||2.16 (1.93%)|
|1y Target Est||121.90|
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.
Senseonics Holdings Inc. has slapped a new label on its blood-sugar monitoring system, a move that boils down to one thing for diabetes patients: fewer finger sticks. The Germantown company — whose implantable continuous glucose monitoring (CGM) system senses a person’s glucose levels to determine if he or she needs insulin, food or exercise — is starting to market the product as an alternative to the decades-old step of pricking a finger multiple times a day to elicit a drop of blood. Senseonics (NYSE: SENS) earned that right to market its Eversense CGM system as a replacement for finger sticks to measure glucose, per approval by the Food and Drug Administration this past summer.
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
DUBLIN, Dec. 06, 2019 -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share,.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 6,232,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
Investors need to be bold enough to bet on trend-shifting consumption habits emanating from Industry 4.0, which will stand them in good stead.
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
At Insider Monkey, we pore over the filings of around 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this article, […]
Last week saw the newest quarterly earnings release from Medtronic plc (NYSE:MDT), an important milestone in the...
Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD.
Medtronic stock briefly edged into a buy zone in Tuesday trades after the medical technology company topped Wall Street's quarterly expectations and raised its full-year earnings outlook.
U.S. stocks slipped back from record highs on Wednesday on disappointing earnings results and doubts about a U.S. - China trade deal
Zacks.com featured highlights include: Medtronic Public, Arconic, Nasdaq, Hewlett Packard and Target
Medtronic (MDT) delivered earnings and revenue surprises of 2.34% and 0.38%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?